4//SEC Filing
McClellan Michael James 4
Accession 0001209191-19-016089
CIK 0000818686other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 7:28 AM ET
Size
10.0 KB
Accession
0001209191-19-016089
Insider Transaction Report
Form 4
McClellan Michael James
EVP, Chief Financial Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2019-03-03+1,049→ 12,693.272 total - Sale
Ordinary Shares
2019-03-04$16.88/sh−363$6,129→ 12,330.272 total - Exercise/Conversion
Restricted Share Units
2019-03-03−1,049→ 2,099 total→ Ordinary Shares (1,049 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.130, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on March 3, 2017, with 1,049 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,050 vesting on Mach 3, 2021.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001721544
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 7:28 AM ET
- Size
- 10.0 KB